Cargando…

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?

PURPOSE: Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ntentas, Georgios, Dedeckova, Katerina, Andrlik, Michal, Aznar, Marianne C., George, Ben, Kubeš, Jiří, Darby, Sarah C., Cutter, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493042/ https://www.ncbi.nlm.nih.gov/pubmed/30708133 http://dx.doi.org/10.1016/j.prro.2019.01.006

Ejemplares similares

Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection
por: Ntentas, Georgios, et al.
Publicado: (2022)

Pencil Beam Scanning (PBS) Intensity-Modulated Proton Therapy (IMPT) Chemoradiotherapy for Anal Canal Cancer—Single Institution Experience
por: Vítek, Pavel, et al.
Publicado: (2021)

Pencil‐beam scanning proton therapy for the treatment of glomus jugulare tumours
por: Kubeš, Jiří, et al.
Publicado: (2022)

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022)

5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer—A Retrospective Analysis
por: Kubeš, Jiri, et al.
Publicado: (2023)

P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
por: Geurts, Yvonne M.G., et al.
Publicado: (2022)

P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
por: Shakir, Rebecca, et al.
Publicado: (2022)

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
por: Houlihan, Orla A., et al.
Publicado: (2022)

Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma
por: Geurts, Yvonne M., et al.
Publicado: (2023)

Long‐term hospitalisation rates among 5‐year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study
por: Rugbjerg, Kathrine, et al.
Publicado: (2017)

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
por: Jones, David A., et al.
Publicado: (2022)

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma
por: Cutter, David J., et al.
Publicado: (2021)

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
por: Shakir, Rebecca, et al.
Publicado: (2022)

The role of motion management and position verification in lymphoma radiotherapy
por: Aznar, Marianne, et al.
Publicado: (2021)

P068: A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
por: Marková, Jana, et al.
Publicado: (2022)

Proton linear energy transfer and variable relative biological effectiveness for adolescent patients with Hodgkin lymphoma
por: Rechner, Laura Ann, et al.
Publicado: (2023)

Pericardial Effusion during Proton Therapy in a Patient with Chemorefractory Hodgkin Lymphoma
por: Way, Ashley, et al.
Publicado: (2021)

Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
por: Cutter, David J., et al.
Publicado: (2015)

Proton therapy in the management of non-Hodgkin lymphoma
por: Sachsman, Suzanne, et al.
Publicado: (2015)

Which Patients Would Most Likely to Benefit: MIGS or MEGS, Which One Is It?
por: Sheheitli, Huda, et al.
Publicado: (2019)

Which symptoms contribute the most to patients’ perception of health in multiple sclerosis?
por: Green, Rivka, et al.
Publicado: (2017)

Pulmonary Function after Proton Therapy for Hodgkin Lymphoma
por: O'steen, Lillie, et al.
Publicado: (2019)

Which Benefits Are Mentioned Most Often in Drug Development Publications?
por: Strüver, Vanessa
Publicado: (2017)

Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma
por: Hoppe, B. S., et al.
Publicado: (2017)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

Antimicrobial prophylaxis for vesicoureteral reflux: which subgroups of children benefit the most?
por: Zhao, Beibo, et al.
Publicado: (2023)

Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives
por: Loap, Pierre, et al.
Publicado: (2021)

Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold
por: Rechner, Laura Ann, et al.
Publicado: (2017)

PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?
por: Rossi, Cédric, et al.
Publicado: (2019)

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
por: Kruse, Vibeke, et al.
Publicado: (2013)

Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit?
por: Kovacs, Boldizsar, et al.
Publicado: (2018)

Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
por: Surma, Stanisław, et al.
Publicado: (2022)

Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
por: Toltz, Allison, et al.
Publicado: (2015)

Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence
por: Loap, Pierre, et al.
Publicado: (2021)

Proton Beam Therapy for Early Breast Cancer: A Systematic Review and Meta-analysis of Clinical Outcomes
por: Holt, Francesca, et al.
Publicado: (2023)

Phagocytized Neutrophil Fragments in the Bone Marrow: A Phenomenon Most Commonly Associated with Hodgkin Lymphoma
por: Arnold, Michael A., et al.
Publicado: (2014)

Impact of Helicopter Emergency Medical Service in Traumatized Patients: Which Patient Benefits Most?
por: Andruszkow, Hagen, et al.
Publicado: (2016)

Therapy Selection for Hodgkin Lymphoma in Sickle Cell Disease: balancing risks and benefits
por: Fraley, Claire E., et al.
Publicado: (2022)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

Deep inspiration breath-hold for mediastinal lymphoma patients: Evaluation of a 5-year service
por: Jones, Katie S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_66tnb3gbcdsirs3etqa7mnm4oe